GENOS DOO ZA VJESTACENJE I ANALIZU

Their core work

Genos is a Croatian SME specializing in high-throughput glycan analysis — the study of sugar molecules attached to proteins, which serve as biomarkers for disease. Their core capability is glycomics profiling, particularly IgG glycosylation analysis, which they apply to diagnostics and precision medicine across cancer, autoimmune, and inflammatory diseases. They provide analytical services and glycan data to large European research consortia, functioning as a specialized laboratory partner that generates molecular-level data other groups cannot easily produce. Their work spans from colorectal cancer diagnostics to personalized treatment models for chronic inflammatory conditions.

What they specialise in

How they've shifted over time

Genos entered H2020 with a clear glycomics identity — their 2015-2017 projects (GlyCoCan, GlySign) focused squarely on glycosylation analysis for cancer diagnostics and precision medicine. From 2017 onward, they expanded into chronic inflammatory and autoimmune diseases (SYSCID, 3TR), applying their glycan profiling within broader multi-omics and systems medicine frameworks. By their most recent project (3TR, starting 2019), keywords like single-cell data, integrative genomics, and agent-based modeling indicate a shift from pure wet-lab glycomics toward computational disease modeling and data integration.

Genos is evolving from a glycomics laboratory into a data-rich precision medicine partner, increasingly contributing computational and integrative analysis alongside their glycan profiling services.

How they like to work

Genos operates exclusively as a participant — they have never coordinated an H2020 project, which is typical for a specialized SME providing analytical services to larger consortia. With 131 unique partners across 19 countries from just 6 projects, they join large, diverse consortia rather than small focused teams. This pattern suggests they are a trusted specialist that consortium coordinators actively recruit when glycomics data is needed.

Genos has built an extensive network of 131 unique consortium partners spanning 19 countries, remarkably broad for a company with only 6 projects. Their network is pan-European with no visible geographic clustering, reflecting the demand-driven nature of their specialized analytical services.

What sets them apart

Genos brings a rare and highly specific capability — high-throughput glycan profiling — that very few organizations in Europe can match at scale. Based in Croatia, they offer this niche expertise at competitive rates while participating in top-tier health research consortia. For consortium builders, Genos fills a hard-to-replace analytical gap: if your project needs glycomics data linked to disease biomarkers, they are one of the go-to partners on the continent.

Highlights from their portfolio

• SYSCID
  Largest single grant (EUR 886,743) and their entry into systems medicine for chronic inflammatory disease, marking a strategic expansion beyond pure glycomics.
• 3TR
  Most recent and longest-running project (2019-2026), focused on treatment non-response across autoimmune diseases — signals their future direction toward precision medicine and multi-omics.
• GlySign
  Directly represents their core glycomics identity with the clearest link between glycosylation signatures and precision medicine applications.